The purpose of this study is to estimate the sensibility at the growth hormone in vivo at the children presenting a Prader-Willi syndrome (SPW) in comparison with children presenting a deficit in growth hormone (GHD).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Measure of the circulating rates of IGF-I under treatment.
Timeframe: Before starting treatment: baseline (J0)
Measure of the circulating rates of IGF-I under treatment.
Timeframe: 1 month (M1)
Measure of the circulating rates of IGF-I under treatment.
Timeframe: 3 month (M3)
Measure of the circulating rates of IGF-I under treatment.
Timeframe: 6 month (M6)
Measure of the circulating rates of IGF-I under treatment.
Timeframe: 1 year (M12)